BiomX Inc. issued a statement in response to unusual market activity in its common stock, stating no undisclosed material developments or reasons for the activity. NYSE American LLC contacted the company to issue the statement, and BiomX does not plan to comment further on market speculation. BiomX is a clinical-stage company developing phage therapies to target harmful bacteria in chronic diseases. For more information, visit www.biomx.com. Contact Ben Cohen, Head Corporate Communications, at [email protected] for inquiries.

Read more at GlobeNewswire: BiomX Issues Statement Regarding Recent Common Stock